Lazard Asset Management LLC Makes New $1.23 Million Investment in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Lazard Asset Management LLC purchased a new stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 73,189 shares of the company’s stock, valued at approximately $1,225,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Price T Rowe Associates Inc. MD grew its holdings in Centessa Pharmaceuticals by 14.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company’s stock valued at $89,854,000 after purchasing an additional 685,371 shares during the period. Adage Capital Partners GP L.L.C. grew its stake in shares of Centessa Pharmaceuticals by 22.0% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company’s stock valued at $85,744,000 after buying an additional 924,027 shares during the period. Janus Henderson Group PLC grew its stake in shares of Centessa Pharmaceuticals by 279.2% during the 4th quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company’s stock valued at $82,218,000 after buying an additional 3,614,623 shares during the period. Farallon Capital Management LLC increased its holdings in shares of Centessa Pharmaceuticals by 24.3% during the 4th quarter. Farallon Capital Management LLC now owns 3,498,709 shares of the company’s stock worth $58,603,000 after buying an additional 684,391 shares during the last quarter. Finally, Franklin Resources Inc. raised its position in shares of Centessa Pharmaceuticals by 0.3% in the 4th quarter. Franklin Resources Inc. now owns 2,308,546 shares of the company’s stock worth $38,668,000 after buying an additional 6,000 shares during the period. Institutional investors and hedge funds own 82.01% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Guggenheim reissued a “buy” rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Piper Sandler started coverage on Centessa Pharmaceuticals in a report on Monday, March 31st. They set an “overweight” rating and a $38.00 target price for the company. Oppenheimer assumed coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, May 8th. They set an “outperform” rating and a $6.00 target price for the company. Chardan Capital initiated coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, May 8th. They set a “buy” rating and a $30.00 price target on the stock. Finally, Morgan Stanley reissued an “overweight” rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, Centessa Pharmaceuticals has an average rating of “Buy” and a consensus target price of $27.00.

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ:CNTA opened at $12.26 on Tuesday. The business’s 50-day simple moving average is $13.38 and its 200 day simple moving average is $15.56. The company has a market cap of $1.64 billion, a P/E ratio of -8.01 and a beta of 1.53. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. Centessa Pharmaceuticals plc has a one year low of $7.75 and a one year high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.15. On average, sell-side analysts forecast that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Insider Activity at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider David M. Chao sold 7,000 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $17.17, for a total value of $120,190.00. Following the transaction, the insider now directly owns 225,007 shares of the company’s stock, valued at $3,863,370.19. This represents a 3.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Saurabh Saha sold 55,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $15.93, for a total transaction of $876,150.00. Following the sale, the chief executive officer now directly owns 331,017 shares of the company’s stock, valued at $5,273,100.81. The trade was a 14.25% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 165,398 shares of company stock valued at $2,600,342. Corporate insiders own 7.09% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.